Cara Therapeutics Inc (CARA)
0.305
+0.02
(+5.94%)
USD |
NASDAQ |
Sep 27, 16:00
0.2976
-0.01
(-2.43%)
After-Hours: 20:00
Cara Therapeutics SG&A Expense (Annual): 27.65M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 27.65M |
| December 31, 2022 | 30.13M |
| December 31, 2021 | 29.28M |
| December 31, 2020 | 21.75M |
| December 31, 2019 | 17.66M |
| December 31, 2018 | 15.24M |
| December 31, 2017 | 11.80M |
| Date | Value |
|---|---|
| December 31, 2016 | 8.607M |
| December 31, 2015 | 7.378M |
| December 31, 2014 | 5.82M |
| December 31, 2013 | 3.153M |
| December 31, 2012 | 2.462M |
| December 31, 2011 | 2.407M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
17.66M
Minimum
2019
30.13M
Maximum
2022
25.29M
Average
27.65M
Median
2023
SG&A Expense (Annual) Benchmarks
| Perspective Therapeutics Inc | 21.06M |
| Alaunos Therapeutics Inc | 12.22M |
| Seelos Therapeutics Inc | 12.58M |
| Oragenics Inc | 5.452M |
| Cocrystal Pharma Inc | 5.99M |